Circular Genomics Readying to Launch Zoloft Response Diagnostic Based on Circular RNA Biomarker

jaya40436
Jul 27, 2023
1 min read

Updated: Jul 23, 2024

NEW YORK, NY., July 27, 2023 (GenomeWeb) -- Molecular diagnostics startup Circular Genomics has identified a new biomarker that can predict which patients are likely to respond to Pfizer's antidepressant Zoloft (Sertraline).

View Remaining Article at GenomeWeb

Paul Sargeant, PhD, CEO of Circular Genomics Presents at LSI USA '25 - "Circular RNA Biomarkers for Depression Treatment"

Circular Genomics is at the forefront of revolutionizing healthcare by leveraging circular RNA to develop advanced diagnostic tools,...

5 Promising RNA Biotech Companies To Watch in 2025

Circular Genomics: Innovative RNA Solutions to Lead a New Era in Mental Health RNA, often referred to as the “messenger molecule,” plays...

Podcast: "Revolutionizing Depression Treatment with Dr. Nikolaos Mellios"

Circular Genomics' Chief Scientific Officer, Dr. Nikolaos Mellios, M.D., PhD, joins Steven Schwartz on the Concierge Medical Marketing...

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.